Comparison of Adjuvant Efficacy of Chitosan and Aluminum Hydroxide for Intraperitoneally Administered Inactivated Influenza H5N1 Vaccine

被引:20
作者
Chang, Haiyan [2 ]
Li, Xiaoman [2 ]
Teng, Yong [2 ]
Liang, Yan [2 ]
Peng, Bo [2 ]
Fang, Fang [2 ]
Chen, Ze [1 ,2 ,3 ]
机构
[1] Shanghai Inst Biol Prod, Shanghai 200052, Peoples R China
[2] Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China
[3] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
AVIAN INFLUENZA; A H5N1; ANTIBODY-RESPONSES; VIRUS-VACCINE; IMMUNOGENICITY; THREAT; TRANSMISSION; DERIVATIVES; PROTECTION; SAFETY;
D O I
10.1089/dna.2009.0977
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A safe and effective adjuvant is important to develop vaccines against highly pathogenic avian influenza virus. Chitosan, a derivative from the natural amino polysaccharide chitin, has been proved to be an effective adjuvant for inactivated influenza virus vaccine. In this study, protective immunity in mice provided by chitosan-adjuvanted inactivated H5N1 vaccine was compared with that from an aluminum hydroxide-adjuvanted one. Mice were injected intraperitoneally once or twice with various dosages of inactivated vaccine alone or in combination with an adjuvant (chitosan or aluminum hydroxide). To test the immunization effect, mice were challenged with a lethal dose of H5N1 virus. The results showed that the adjuvanted vaccines were more effective than adjuvant-free ones in inducing humoral immune responses and protecting mice against lethal challenge. Chitosan was comparable to the alum adjuvant in efficacy. These findings indicated that chitosan might be a candidate adjuvant for parenteral administration of inactivated influenza vaccines.
引用
收藏
页码:563 / 568
页数:6
相关论文
共 40 条
  • [1] Epidemiological Findings of Outbreaks of Disease Caused by Highly Pathogenic H5N1 Avian Influenza Virus in Poultry in Egypt During 2006
    Aly, M. M.
    Arafa, A.
    Hassan, M. K.
    [J]. AVIAN DISEASES, 2008, 52 (02) : 269 - 277
  • [2] Arai K., 1968, B TOKAI REG FISH RES, V56, P89, DOI [10.3390/md12126236, DOI 10.3390/MD12126236]
  • [3] Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens
    Bacon, A
    Makin, J
    Sizer, PJ
    Jabbal-Gill, I
    Hinchcliffe, M
    Illum, L
    Chatfield, S
    Roberts, M
    [J]. INFECTION AND IMMUNITY, 2000, 68 (10) : 5764 - 5770
  • [4] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
    Bresson, Jean-Louis
    Perronne, Christian
    Launay, Odile
    Gerdil, Catherine
    Saville, Melanie
    Wood, John
    Hoeschler, Katja
    Zambon, Maria C.
    [J]. LANCET, 2006, 367 (9523) : 1657 - 1664
  • [5] H5N1 virus outbreak in migratory waterfowl
    Chen, H
    Smith, GJD
    Zhang, SY
    Qin, K
    Wang, J
    Li, KS
    Webster, RG
    Peiris, JSM
    Guan, Y
    [J]. NATURE, 2005, 436 (7048) : 191 - 192
  • [6] Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein
    Chen, Z
    Yoshikawa, T
    Kadowaki, S
    Hagiwara, Y
    Matsuo, K
    Asanuma, H
    Aizawa, C
    Kurata, T
    Tamura, S
    [J]. JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 2559 - 2564
  • [7] The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology
    Cinatl, Jindrich, Jr.
    Michaelis, Martin
    Doerr, Hans W.
    [J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2007, 196 (04) : 191 - 201
  • [8] The threat of avian influenza A (H5N1). Part I: epidemiologic concerns and virulence determinants
    Cinatl, Jindrich, Jr.
    Michaelis, Martin
    Doerr, Hans W.
    [J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2007, 196 (04) : 181 - 190
  • [9] The threat of avian influenza A (H5N1). Part IV: development of vaccines
    Cinatl, Jindrich, Jr.
    Michaelis, Martin
    Doerr, Hans W.
    [J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2007, 196 (04) : 213 - 225
  • [10] The global impact of vaccines containing aluminium adjuvants
    Clements, CJ
    Griffiths, E
    [J]. VACCINE, 2002, 20 : S24 - S33